gip glp 1 receptor agonist drugs The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology The Effects of Dual GLP-1/GIP

Carnitine: a novel health factor an overview

Outcomes The primary outcome in our analysis was change in HbA1c from baseline, and the secondary outcome was weight change from baseline

DOI:10.1093/ajcn/50.2.301

Supplies Needed Plan is based on an 816 week 5x per week protocol taking the standard dose 10mg Blend Vial (5mg CJC-1295 + 5mg Ipamorelin) 8 weeks 2 vials 12 weeks 3 vials 16 weeks 4 vials Insulin Syringes 8/week total 8 weeks 40 12 weeks 60 16 weeks 80 Bacteriostatic Water 8 weeks: ~6 mL (1 bottle) 12 weeks: ~9 mL (1 bottle) 16 weeks: ~12 mL (2 bottles) Alcohol Swabs 8 weeks ~40 12 weeks ~60 16 weeks ~80 Protocol Overview Goal: Support natural growth hormone release and improve recovery, body composition, and metabolic health Schedule: Daily injections for 812 weeks (extendable to 16 weeks) Dose Range: 500 mcg (250 mcg of each peptide) 5x per week Reconstitution: 2.0 mL per vial Storage: Refrigerated after mixing